A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

(2015) David S. Hong et al.   Oncotarget

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

(2014) Jennifer J. Knox et al.   INVESTIGATIONAL NEW DRUGS

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

(2013) David S. Hong et al.   Clinical Genitourinary Cancer

Phase II trial of temsirolimus in patients with metastatic breast cancer

(2012) Gini F. Fleming et al.   BREAST CANCER RESEARCH AND TREATMENT

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

(2012) Brian Rini et al.   CANCER

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

(2010) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

(2009) Premal H. Patel et al.   Clinical Genitourinary Cancer

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER